Table 1 Baseline demographics and disease characteristics among patients receiving rituximab or anti-TNF agents, and standardized differences

 White, %

87.6

83.5

0.114

84.4

87.3

0.084

 Female, %

81.1

79.2

0.049

82.9

81.0

0.051

 Age, mean (SD), years

57.8 (11.7)

56.1 (12.4)

0.139

57.6 (11.7)

58.0 (11.5)

0.037

 Medicare, %

37.7

29.4

0.176

33.7

39.0

0.111

 Medicaid, %

7.2

6.4

0.032

7.3

6.3

0.039

 Private insurance, %

76.6

78.7

0.050

76.1

74.6

0.034

 No insurance, %

1.1

2.3

0.090

1.5

1.5

0.000

 Cardiovascular disease, %

11.3

7.3

0.137

9.8

11.7

0.063

 Cancer, %

9.4

7.7

0.061

10.2

8.8

0.050

 Diabetes, %

9.8

10.7

0.030

10.2

10.7

0.016

 Disease duration, mean (SD), years

15.4 (10.2)

11.4 (9.4)

0.408

14.6 (10.3)

15.1 (10.5)

0.047

 Tender joint count, mean (SD)

9.6 (7.3)

8.7 (7.3)

0.117

9.5 (7.2)

9.1 (7.8)

0.058

 Swollen joint count, mean (SD)

8.0 (5.6)

7.5 (5.7)

0.097

7.9 (5.5)

7.4 (5.8)

0.086

 Patient global assessment, mean (SD)

54.3 (23.6)

50.6 (25.0)

0.154

53.2 (23.4)

52.7 (25.5)

0.023

 Physician global assessment, mean (SD)

42.7 (20.2)

39.3 (20.1)

0.169

42.3 (19.7)

39.8 (19.1)

0.130

 Patient pain, mean (SD)

56.5 (24.5)

53.2 (25.5)

0.132

55.3 (24.8)

53.0 (26.2)

0.093

 Disability index (mHAQ), mean (SD)

0.78 (0.5)

0.64 (0.5)

0.270

0.74 (0.5)

0.72 (0.5)

0.040

 Clinical Disease Activity Index, mean (SD)

27.3 (12.5)

25.2 (11.9)

0.172

27.0 (12.0)

25.7 (12.3)

0.100

 Prior nbDMARDs, n, mean

1.6

1.1

0.396

1.4

1.4

0.031

 Prior use of ≥2 anti-TNF agents, %

63.0

26.6

0.786

54.6

54.6

0.000

 Prior use of non–anti-TNF biologic agents, %

40.8

13.0

0.657

31.7

33.2

0.031

 Prednisone, %

43.8

29.3

0.303

39.0

38.5

0.010

 Methotrexate, %

57.7

55.9

0.037

57.1

51.7

0.108

 Non-methotrexate nbDMARD, %

29.1

24.8

0.095

29.8

30.2

0.011